SLU-PP-332: The Synthetic ERR Agonist for Metabolic Adaptation Research

SLU-PP-332 represents a sophisticated approach to understanding and potentially manipulating cellular energy metabolism through pharmacological intervention. Developed by researchers at Saint Louis University—hence the “SLU” designation—this synthetic small molecule has emerged as one of the most well-characterized agonists of the estrogen-related receptor (ERR) family. Unlike traditional peptide hormones or growth factors, SLU-PP-332 operates at the nuclear level, directly modulating gene expression programs that govern mitochondrial function, oxidative metabolism, and cellular adaptation to energy demands.

Development and Chemical Nature

The development of SLU-PP-332 emerged from research into the transcriptional control of metabolism at Saint Louis University. The compound is a hydrazide derivative specifically designed to interact with the ligand-binding domains of ERR family members. Despite its classification alongside research peptides in many contexts, SLU-PP-332 is technically a small-molecule organic compound with distinct pharmaceutical properties from peptide therapeutics.

The designation “PP-332” reflects its origins in the university’s chemical library and screening programs. Research published in PubMed and ScienceDirect describes SLU-PP-332 as a “well-established exercise mimetic and widely used chemical probe for ERR activation,” highlighting its importance as a research tool for metabolic studies.

Mechanism of Action: ERR Family Activation

SLU-PP-332 functions as a pan-agonist, meaning it activates all three members of the estrogen-related receptor family: ERRα, ERRβ, and ERRγ. Despite their name, ERRs are not estrogen receptors and do not bind estrogen. Instead, they are orphan nuclear receptors—transcription factors that regulate gene expression in response to metabolic signals rather than classical hormones.

The mechanism of SLU-PP-332 involves several coordinated steps:

Ligand Binding: The compound binds to the ligand-binding domain of ERR proteins, stabilizing the receptor in its active conformation. This binding occurs in a hydrophobic pocket distinct from the DNA-binding domain.

Coactivator Recruitment: Upon binding, SLU-PP-332 promotes interaction between ERR receptors and transcriptional coactivators, particularly PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). This partnership is crucial for metabolic regulation, as PGC-1α serves as the master regulator of mitochondrial biogenesis.

Gene Transcription: The activated ERR-PGC-1α complex binds to specific DNA sequences (ERR response elements) in the promoter regions of target genes, initiating transcription of proteins involved in energy metabolism.

According to research documented in Superpower, ERRs are “constitutively active transcription factors that regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism.” SLU-PP-332 was specifically designed to activate all three ERR subtypes simultaneously, enabling researchers to study the integrated effects of ERR pathway activation.

Exercise Mimetic Properties

The most intriguing aspect of SLU-PP-332 is its classification as an “exercise mimetic”—a compound that reproduces cellular adaptations associated with aerobic physical activity through pharmacological means rather than mechanical work. This concept has generated significant interest in metabolic research and sports science.

Endurance exercise naturally activates ERRα and PGC-1α signaling, leading to:

• Increased mitochondrial number and function
• Enhanced fatty acid oxidation capacity
• Shift toward oxidative muscle fiber types
• Improved cellular respiration and energy efficiency
• Greater oxidative phosphorylation enzyme expression

SLU-PP-332 appears to activate these same pathways without physical exertion. Research published in PeptideDeck confirms that “ERR alpha is one of the master switches activated by endurance training,” and SLU-PP-332 provides a pharmacological means of activating this switch directly.

However, researchers caution that exercise produces complex systemic adaptations involving multiple tissues and signaling pathways that a single compound cannot fully replicate. The “exercise mimetic” label refers specifically to the transcriptional programs activated in muscle and metabolic tissues, not the complete physiological response to training.

Mitochondrial Biogenesis and Metabolic Effects

The primary downstream effect of SLU-PP-332 is stimulation of mitochondrial biogenesis—the creation of new mitochondria within cells. This process, driven by PGC-1α activation, involves coordinated expression of both nuclear and mitochondrial genes to produce functional organelles capable of oxidative phosphorylation.

Key metabolic effects documented in research include:

Fatty Acid Oxidation: SLU-PP-332 upregulates enzymes involved in beta-oxidation, the process by which fatty acids are broken down to produce acetyl-CoA for energy production. This shift toward lipid metabolism is characteristic of endurance-trained muscle.

Oxidative Phosphorylation Enhancement: The compound increases expression of electron transport chain components and ATP synthase, improving the efficiency of cellular respiration and energy production.

Cytochrome C Induction: As documented in The Preptide, SLU-PP-332 increases expression of cytochrome C and other oxidative phosphorylation enzymes, enhancing cellular respiratory capacity.

Metabolic Flexibility: By enhancing mitochondrial function, SLU-PP-332 may improve the ability of cells to switch between carbohydrate and lipid fuel sources—a hallmark of metabolic health.

Research Applications and Experimental Models

SLU-PP-332 serves as a valuable research tool across multiple domains:

• Metabolic Disease Research: Investigation of mitochondrial dysfunction in obesity, diabetes, and metabolic syndrome
• Exercise Physiology: Studies of transcriptional adaptations to endurance training
• Mitochondrial Biology: Research on biogenesis, dynamics, and function of mitochondria
• Nuclear Receptor Pharmacology: Structure-activity relationship studies and ligand design
• Aging Research: Investigation of age-related metabolic decline and mitochondrial dysfunction
• Cardiac Metabolism: Studies of energy metabolism in heart tissue

The compound’s ability to selectively activate ERR pathways without the confounding effects of exercise itself makes it particularly useful for isolating specific molecular mechanisms underlying metabolic adaptation.

Chemical Optimization and Structure-Activity Relationships

Recent research has focused on optimizing SLU-PP-332 to better understand the structural features governing its potency, efficacy, and selectivity. A 2025 study published in ScienceDirect described “chemical optimization of the exercise mimetic SLU-PP-332” that identified key structural features governing ERRα/ERRγ potency and selectivity.

These optimization efforts aim to:

• Improve metabolic stability for enhanced duration of action
• Increase selectivity between ERR isoforms
• Reduce off-target effects
• Enhance drug-like properties while maintaining biological activity

Such research advances our understanding of nuclear receptor pharmacology and may lead to improved research tools or therapeutic candidates.

Comparison with Other Metabolic Compounds

SLU-PP-332 occupies a unique position among metabolic research compounds. Unlike AMPK activators (such as AICAR or exercise mimetics like MOTS-c) that work through kinase signaling, SLU-PP-332 acts directly at the transcriptional level. Unlike PPAR agonists that regulate lipid metabolism through different nuclear receptors, SLU-PP-332 specifically targets the ERR-PGC-1α axis.

This distinct mechanism makes SLU-PP-332 valuable for comparative studies examining different pathways of metabolic regulation. Researchers often use it alongside other compounds to dissect the relative contributions of various signaling networks to metabolic adaptation.

For investigators studying metabolic regulation, mitochondrial function, and exercise adaptations, explore our comprehensive selection at Buy Nova Peptides Shop or visit Buy Nova Peptides for additional research compounds and educational resources.

References and Scientific Literature

1. Yoh, S.M., et al. (2025). “Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.” European Journal of Medicinal Chemistry. PubMed
2. Yoh, S.M., et al. (2025). “Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.” ScienceDirect. ScienceDirect
3. Ikeda, Y., et al. (2023). “ERR signaling in skeletal muscle mitochondrial function.” Journal of Molecular Endocrinology.
4. Superpower. “SLU-PP-332: A Pan-ERR Agonist Research Tool Compound.” Superpower
5. PeptideDeck. “SLU-PP-332: Benefits, Dosage, Side Effects and How the Exercise Mimetic Works.” PeptideDeck
6. The Preptide. “SLU-PP-332.” The Preptide
7. AminoCore Research. “SLU-PP-332: The Science Behind Exercise Mimetics, Metabolic Reprogramming, Mitochondrial Medicine.” AminoCore Research
8. ResearchGate. “SLU-PP-332 AND RELATED ERRα AGONISTS: A FOCUSED MINIREVIEW OF METABOLIC REGULATION AND THERAPEUTIC POTENTIAL.” ResearchGate
9. Google Scholar. “SLU-PP-332 ERR agonist exercise mimetic mitochondrial biogenesis.” Google Scholar

Disclaimer: This content is provided for educational and research purposes only. SLU-PP-332 is an investigational compound not approved for human consumption or therapeutic use. This information does not constitute medical advice, treatment recommendations, or claims of efficacy. Always consult qualified healthcare professionals and comply with applicable regulations governing research compounds.